Literature DB >> 2611899

Masseter and temporalis electromyographic activity in asymptomatic, subclinical, and temporomandibular joint dysfunction patients.

R O Gervais, G W Fitzsimmons, N R Thomas.   

Abstract

The research and clinical literature on biofeedback treatment of temporomandibular joint (TMJ) dysfunction is devoid of normative or comparative electromyographic (EMG) studies examining muscle activity in either patient or normal samples. For the present study, resting EMG levels for each masseter and temporalis were obtained from three groups of subjects: asymptomatic (female, N = 24, mean age = 26.4); subclinical (female, N = 31, mean age = 28.6); and patient (N = 61, female 70%, mean age = 31.9). A Biocomp 2001 biofeedback system was used to gather the EMG data from each of the four sites during a six- to eight-minute resting baseline period. The patient group demonstrated significantly higher EMG activity than the asymptomatic or subclinical groups for all variables except the right masseter (F (8,220) = 6.65, p less than 0.001). The temporalis was found to be the site of greatest EMG activity more frequently than the masseter. These findings strengthen diagnostic and assessment procedures and criteria, as well as suggest alternate treatment and research protocols.

Entities:  

Mesh:

Year:  1989        PMID: 2611899     DOI: 10.1080/08869634.1989.11678268

Source DB:  PubMed          Journal:  Cranio        ISSN: 0886-9634            Impact factor:   2.020


  2 in total

1.  An in vivo electromyographic evaluation of pain relief using different therapies in masticatory myalgia patients.

Authors:  Parvathi K Balakrishnan; Sowmya M Kumar; Purushotham Chippala; Chethan Hegde
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-10-31

2.  Comparison of immediate complete denture, tooth and implant-supported overdenture on vertical dimension and muscle activity.

Authors:  Farhan Khalid Shah; Ashraf Gebreel; Ali Hamed Elshokouki; Ahmed Ali Habib; Amit Porwal
Journal:  J Adv Prosthodont       Date:  2012-05-30       Impact factor: 1.904

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.